Literature DB >> 10447114

The cortisol-cortisone shuttle in children born with intrauterine growth retardation.

M Houang1, G Morineau, Y le Bouc, J Fiet, M Gourmelen.   

Abstract

We evaluated the involvement of a possible dysfunction of 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) in the fetal growth retardation and poor growth rates of children born with intrauterine growth retardation (IUGR). Children with IUGR have a nephron deficit and are also at risk of developing cardiovascular diseases, high blood pressure, glucose intolerance, and dyslipidemia later in life. The major site of 11beta-HSD2 production is the kidney and its deficit causes hypertension. We investigated plasma concentrations of cortisol (F) and cortisone (E) and the F/E ratio in 26 control children and in 40 IUGR children without catch-up growth. We also determined cholesterol, HbA1C, insulin, and glucose levels in plasma. Mean F values were 106 +/- 54.2 ng/mL in control children and 114.6 +/- 53.2 ng/mL in IUGR children. Mean E values were 19.5 +/- 7.1 ng/mL in control children and 17.9 +/- 6.85 ng/mL in IUGR children. The mean F/E ratio for control children was 5.5 +/- 1.7. Eight (20%) of the IUGR children (IUGR children of group 1) had high F/E ratios more than 2 SD above the normal mean: 13.15 +/- 4.26, (p < 0.0001) as compared to control children, whereas the other 32 children (IUGR children of group 2) had normal F/E ratios: 5.40 +/- 1.43 (p = 0.68). Childhood height was significantly lower for group 1 than group 2 children (-3.63 SD and -2.92 SD, respectively: p < 0.01) and was negatively correlated with the F/E ratio (p < 0.01). Systolic blood pressure was higher for group 1 (p = 0.005) and for group 2 (p = 0.015) than for control children. The diastolic pressure in IUGR children of group 1 was higher than that in control children (p = 0.013) and slightly higher than that in group 2 (p = 0.1, ns). Cholesterol concentrations were higher in group 1 than in group 2 (p = 0.029), and controls (p = 0.017) and correlated positively with F/E (0.02 < p < 0.05). Fasting insulin concentrations were higher in group 1 than in group 2 (ns) and controls (ns). There was no difference in mean fasting glucose concentrations, or HbA1C between the three groups. Twenty percent of our children with IUGR and poor growth rates had high F/E ratios, suggesting a possible partial 11beta-HSD2 deficit. Whether these children are at high risk of developing cardiovascular diseases as adults remains to be further evaluated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10447114     DOI: 10.1203/00006450-199908000-00011

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  5 in total

Review 1.  Prenatal programming-effects on blood pressure and renal function.

Authors:  Eberhard Ritz; Kerstin Amann; Nadezda Koleganova; Kerstin Benz
Journal:  Nat Rev Nephrol       Date:  2011-02-01       Impact factor: 28.314

2.  Fetal growth restriction alters transcription factor binding and epigenetic mechanisms of renal 11beta-hydroxysteroid dehydrogenase type 2 in a sex-specific manner.

Authors:  Mariana Baserga; Rajwinderjit Kaur; Merica A Hale; Allyson Bares; Xing Yu; Christopher W Callaway; Robert A McKnight; Robert H Lane
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-04-28       Impact factor: 3.619

Review 3.  Low nephron number--a new cardiovascular risk factor in children?

Authors:  Kerstin Amann; Christian Plank; Jörg Dötsch
Journal:  Pediatr Nephrol       Date:  2004-12       Impact factor: 3.714

4.  Prenatal Programming and Epigenetics in the Genesis of the Cardiorenal Syndrome.

Authors:  Ravi Nistala; Melvin R Hayden; Vincent G Demarco; Erik J Henriksen; Daniel T Lackland; James R Sowers
Journal:  Cardiorenal Med       Date:  2011-10-12       Impact factor: 2.041

5.  Association of Serum Total Osteocalcin Concentrations With Endogenous Glucocorticoids and Insulin Sensitivity Markers in 12-Year-Old Children: A Cross-Sectional Study.

Authors:  Satu Seppä; Sirpa Tenhola; Raimo Voutilainen
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-19       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.